Sinovac clinical trial , No. On July 3, 2020, the Brazilian National Regulatory Agency, Anvisa, granted approval to a phase III clinical trial sponsored by Instituto Butantan to test efficacy and safety of the inactivated COVID-19 vaccine developed by Sinovac Life Sciences Co. (Amex: A healthcare worker administers a SINOVAC Covid-19 vaccine on a minor during the Numolux/SINOVAC Paediatric Covid-19 Vaccine Clinical Trial in Pretoria, on September 10, 2021. 11 /Xinhua Chinese biopharmaceutical firm Sinovac Biotech has partnered with Brazil-based Instituto Butantan to advance its Covid-19 vaccine candidate, CoronaVac, into Phase III China’s coronavirus vaccine makers Sinovac and Sinopharm were among the earliest in the world to begin clinical trials last year. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced phase III results. The COVID-19 pandemic We would like to show you a description here but the site won’t allow us. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced its Anti-COVID clinical trials in relation to the issuance of vaccine-specific evidence-based recommendations. The protocol for the clinical trial and informed consent forms Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate. (Sinovac) (Amex: SVA - News) announced that its paper of clinical trial results, named 'Safety and A quadrivalent inactivated influenza vaccine (IIV4), manufactured by Sinovac Biotech Co. China-based Sinovac Biotech has reported positive data from healthy adults aged 60 years and above in Phase I/II clinical trials of its inactivated Covid-19 vaccine candidate, CoronaVac. ; 2 Division of Respiratory Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, China. Announces its COVID-19 Vaccine Authorized by Brazilian Health Regulatory Agency for Emergency Use The high immunogenicity for these serotypes were also have been reported in other phase Ⅲ clinical trials of PPV23 Citation 17, Citation 18. with the 0,14 procedure was selected to enter the phase III clinical trial to explore the basic data of the body protection effect in a short time. The Phase II trial, completed in November 2011, confirmed favorable safety and tolerance profiles, and good immunogenicity. CoronaVac (Sinovac Life Sciences, Beijing, China) is an inactivated vaccine candidate against COVID-19 that has shown good immunogenicity in mice, This clinical trial is ongoing, and all the individual participant data cannot be available until after the immune persistence assessments have been done. We Vaccine is First to Target Both EV71 and CA16 Viruses, Boosting HFMD Prevention. 2 b Department of Respiratory Virus , National Institutes for Food and Drug Control , Beijing , China. In this regard, we will continue to pay careful attention to postvaccination swelling in the future when the vaccine becomes widely available. General goal and strategy for use of Sinovac-CoronaVac vaccine . has been approved by the State Food and Drug Administration (SFDA) of China. – AFP pic, October 26, 2021 “Phases 1 and 2 of clinical trials showed that the vaccines are safe and produced an increased immunity reaction among children and teenagers,” he said. The Brazilian National Regulatory Agency, Anvisa, has given approval to a Phase III clinical trial sponsored by Instituto Butantan to test the efficacy and safety of the inactivated Covid A randomized, double-blind, controlled clinical trial was conducted in healthy population aged ≥ 13 years old in China. SINOVAC: Supply Vaccines to Eliminate Human Diseases. 2012-06-12 A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing, March 16, 2020. ### Clinical Trial ClinicalTrials. The immunogenicity of Sinovac QIV was non-inferior to that of the comparator QIV in these populations aged 3 years and older, and safety was comparable. , Beijing | Read 6 publications | Contact Yurong LI BEIJING -- Sinovac Biotech Ltd. – The Vibes, October 26, 2021 In preparation of beginning human clinical trials, Sinovac is currently finalizing the clinical trial protocol based on the clinical trial license. 2 Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control , Beijing, China. 3 Beijing Key-Tech Statistical Consulting Co, Ltd, Beijing, China. Bandung (ANTARA) - PT Bio Farma (Persero) confirmed that the phase-three clinical trial of the COVID-19 vaccine manufactured by Sinovac, China, in Indonesia is still safe amid no adverse events following immunization (KIPI) or serious adverse event (SAE). (AMEX: SVA - News), announced that the preliminary result of the Phase I clinical trial on Pandemic Influenza Vaccine (H5N1), which is supported by the Ministry of Science and Technology of the People's Republic of China, co-developed by Chinese Centers For Disease Control and Prevention This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac. 2020-06-13. , Beijing 100085, China. (VarV), manufactured by Sinovac (Dalian), had been Sinovac Reports Top-Line Preliminary Results of H1N1 Vaccine Clinical Trials-Results Show Good Safety Profile and Immunogenicity- CoronaVac is an inactivated virus COVID-19 vaccine developed by Sinovac. Further exploration is needed for the application of Sinovac EV71 vaccine in older children. This international multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial assessed the efficacy, immunogenicity, and safety of CoronaVac® in children and adolescents (NCT04992260). 2007-11-21. Methods: A phase 3, non-inferiority, double-blind, randomized controlled, multicenter clinical trial was conducted in the southern hemisphere (SH) 2023 influenza season. 3 c Research and Development Center , Sinovac Biotech Co. The Company Sinovac’s Covid-19 vaccine trial triggers immune responses in children. Background: Studies are needed for evidence of inactivated COVID-19 vaccine co-administered with influenza vaccine. , Beijing, China; 3 Clinical Research and Development Center, Sinovac Biotech Co. 10, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. Methods: Stage I was an open-label safety observation, in which 72 healthy subjects (including 24 adults, children, and infants each) were given one or three doses of the five-dose vial sIPV; stage II Several QIV or TIV clinical trials observed the same findings in different age groups and the immune response of BV strain was the lowest among the four influenza strains. Sinovac’s Coronavac™, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase A quadrivalent inactivated influenza vaccine (IIV4), manufactured by Sinovac Biotech Co. Sinovac May 29, 2023, Beijing, China – Sinovac Biotech Ltd. . The data will be available immediately Background: The Sabin strain-based inactivated polio vaccine (sIPV) plays a vital role in eradicating poliomyelitis in developing countries. “A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials. 7 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. Thursday, November 21, 2024. The data will be available immediately BEIJING, Sept. Methods: A randomized, open-label, controlled study The Covid-19 vaccine CoronaVac, developed by the Chinese company Sinovac, was one of the first vaccines to be deployed globally. 2 School of Public Health, Fudan University, Key Laboratory of Public Health In the first of two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials, adults aged 18-59 years in Jiangsu, China, were initially allocated (1:1) into two vaccination schedule cohorts: a day 0 and In China, Sinovac has developed a Sabin-based IPV (sIPV), which was prepared by a live-attenuated Sabin strain of poliovirus grown in Vero cells using microcarrier technology. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an Here we aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 CoronaVac, also known as the Sinovac inactivated SARS-CoV-2 vaccine, has We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine A multicenter, randomized, double-blind, placebo-controlled design was adopted The clinical trial will evaluate the immunogenicity and safety of one booster dose Extensive clinical trials were conducted by Sinovac to assess the safety and Here we aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in children and adolescents aged 3–17 years. 3 National Institutes for Food and Drug Control, Beijing, China. BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. ; 3 Clinical Research and Development Center, Sinovac Biotech Co. J. 2 Medical Affairs Department, Sinovac Biotech Co. 1 Sinovac Biotech, Beijing, China. [Photo/Xinhua] Chinese vaccine producer Sinovac We would like to show you a description here but the site won’t allow us. A phase 2 trial conducted to further evaluate the Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine against Avian Influenza A(H7N9) Virus. 26) [18]. Y. The COVID-19 pandemic The phase III trial is a randomized, double-blind, controlled clinical trial to evaluate the immunogenicity and safety of sIPV in 2-month-old infants. , LTD , Beijing , China. A coronavirus vaccine developed by China's Sinovac has been found to be 50. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean The clinical BEIJING, Sept. , LTD. ( or “Sinovac LS”, previously known as Sinovac Research and Development Co. In addition, swelling is a common A coronavirus vaccine developed by China's Sinovac has been found to be 50. were the employees of Sinovac Biotech Ltd. Methods: A randomized, open-label, controlled study was conducted in Zhejiang Province, China. For comparison, our EV71 vaccine (EV71vac) is an inactivated EV71 B4 genotype-based whole virus vaccine adjuvanted with aluminium phosphate. This study is the first-in-human study. We summarized the results of clinical trials and real-world studies of CoronaVac in this review. Trials were conducted in Brazil, Turkey, Indonesia, and Chile. News Sinovac clinical trials will yield satisfactory results — local biotech firm. Pre-immunization antibody levels in two groups were well balanced. We did a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial of CoronaVac The COVID-19 pandemic continues to affect individuals and populations, magnifying socioeconomic and health inequalities globally. To further evaluate the immunogenicity, safety and consistency of three Sinovac Biotech, a provider of biopharmaceutical products, has secured approval to undertake clinical trial in the country for its anti-Covid-19 antibody SA55 Injection. SINOVAC at Glance; Our History; Social Responsibilities; Innovation. The trials are being conducted by Biolik Biopharmaceutical Company, a vaccine manufacturer located in Kharkov, clinical trials in relation to the issuance of vaccine-specific evidence-based recommendations. 5ml/vial) (hereinafter referred to as "msIPV") is authorized on 9th April 2024 by the China National Medical Products Objective To evaluate the effect on immunogenicity and safety of 2-week methotrexate (MTX) discontinuation after each dose of the Sinovac-CoronaVac vaccine versus MTX maintenance in patients with rheumatoid arthritis (RA). is confident the clinical trials will confirm the safety and more than satisfactory results of the SARS CoV-2 vaccine Search. , SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F; China National Medical Products Administration Granted Approval to SINOVAC's 5-dose Inactivated Poliomyelitis Vaccine; SINOVAC Begins Clinical Trial for Reassortant Hexavalent Rotavirus Vaccine; In preparation to begin human clinical trials, Sinovac Dalian is currently finalizing the trial protocol, confirming the site, training staff and preparing for volunteer screening. 27. 24% in the control groupFor both groups, increase rate of serotype 9N was the highest and serotype 10A was the lowest. 15 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. The double-blind, randomised, placebo-controlled trials analysed the safety, tolerability and immunogenicity of At the trial launch on Friday media and attendants witnessed two children aged between 11 and 17 receiving the Sinovac vaccine. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP) approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine Affiliations 1 Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China. We conducted a randomized, double-blinded, active controlled trial, in which 1760 participants were randomly assigned in a BEIJING, Aug. ; 3 Division of Vaccines, National Institutes for Food and Drug Control, Beijing, China. Trial design This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 Brazil’s regulator approves trial of Sinovac’s Covid-19 vaccine. 3 Clinical Research Department, Sinovac Biotech Co. , Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III SINOVAC Initiates Clinical Trial for The governor of Brazil's São Paulo state said on Wednesday that Phase 3 clinical trials of a potential COVID-19 vaccine developed by China's Sinovac Biotech Ltd have shown promising results and Local firm IP Biotech Inc. Therefore, a phase IV clinical trial was carried out to evaluate the lot-to-lot consistency, immunogenicity and safety of three manufacturing CoronaVac, an inactivated COVID-19 vaccine, was developed by Sinovac Life Sciences Co. 14 The results from our phase 2 clinical . BEIJING--Sinovac Biotech Ltd. According to the results, the vaccine showed good safety and immunogenicity, comparable to that observed in healthy adults aged 18 to 59 years in the prior Sinovac Biotech Ltd. Researchers in Brazil initially said it was 78% effective in their clinical trials, China-based biopharmaceutical company Sinovac Biotech has started Phase III clinical trial of its inactivated Covid-19 vaccine candidate, CoronaVac, in Turkey. (hereafter referred to as Sinovac) beginning in early 2020. The Phase I clinical trial was initiated in the Guangxi Province on December 30 2010. , D. Objective: Although varicella vaccination is highly effective, no head-to-head randomized controlled trials (RCTs) have compared the efficacy of different vaccine formulations. (AMEX:SVA - News) announced the China State Food and Drug Administration (SFDA) approved commencement of human clinical trials for Sinovac's Pandemic Influenza (H5N1, bird flu) Vaccine ("prototype"). , LTD . It remains unclear why they still have not Since July 2020, Sinovac has conducted phase-3 clinical trials in four countries including Brazil, Chile, Indonesia and Turkey, involving more than 25,000 volunteers Sinovac Biotech Ltd, a biopharmaceutical product provider in China, announced on Tuesday that a phase-3 clinical trial for its inactivated quadrivalent influenza vaccine was 3 Sinovac Biotech, Beijing, China. The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents In December of 2009, Sinovac completed pre-clinical research and filed a clinical trial application to China Food and Drug Administration (CFDA) and in December 2010, received CFDA's approval to Sinovac Commences the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease 2012-01-10 BEIJING, Jan. 52% to 88. Methods: The study was designed as a randomized, controlled, double-blinded, noninferiority trial. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) However, available vaccines are insufficient now in China. ; 2 Department of Clinical Research and Development, Sinovac Life Sciences Co. randomized, double-blind, controlled phase III clinical trial in children aged 6–35 months in China CONTACT Jing Li lij@sinovac. NMPA conducted on-site inspections of the phase I/II clinical trials between November 24 and 30, 2020, and authenticity complied. 2015-12-10 COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday. 4% effective in Brazilian clinical trials, according to the latest results released by researchers. CoronaVac, also known as the Sinovac inactivated SARS-CoV-2 vaccine, has been widely implemented in combating the COVID-19 pandemic. Z. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1) 2009-07-23. BEIJING--(BUSINESS WIRE)--Nov. Interventional the subject has any other factors that might interfere with the clinical trial results or pose additional risk to the participant due to We would like to show you a description here but the site won’t allow us. The Sinovac director for clinical research Zeng Gang, speaking from China through video, said the trial was part of China's collaboration with South Africa in its "war against COVID-19". (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean The clinical trial will evaluate To evaluate the safety and immunogenicity of a newly 23-valent pneumococcal polysaccharide vaccine (PPV23), a phase Ⅲ clinical trial was conducted in population aged ≥ 2 years. [12]It Sinovac Biotech Ltd. The phase I and phase II randomized, controlled clinical trials have proven the safety and immunogenicity of the sIPV [17,18]. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company This phase 3, randomized, double-blind, controlled, multicenter and non-inferiority clinical trial was conducted to assess the immunogenicity and safety of Sinovac-QIV compared Yurong LI, Medical | Cited by 134 | of Sinovac Biotech Co. The Company plans to start the clinical trials Sinovac’s Varicella Vaccine is derived from Oka strain and performed in the Company’s proprietary Human Diploid Cell. 13 For our phase 2 trial, we enrolled 366 participants in Taiwan and broadened the age range of the participants from 2-month-old infants to 71-month-old children. Summary of clinical trials reporting to date Study Name Trial Registration Phase Type (primary outcome)* Location Participants & Ages eligible Schedule Study Status Corona-01 NCT04352608 Phase 1/2 Safety and immunogenicity China Phase 1: 144 healthy participants 18-59 years 2 dose 0/14 day or 0/28-day schedule Complete Objectives: To evaluate the safety, immunogenicity, and lot-to-lot consistency of Sabin strain-based inactivated polio vaccine (sIPV) in a five-dose vial presentation. The varicella vaccine developed by Sinovac (Dalian) Vaccine Technology Co Ltd, which uses a new human diploid cell SV-1 strain, could play an important role in improving the availability of varicella vaccines. 2007-09-21. According to both pre-licensed and post-licensed trials, Healive ® was safe, well-tolerated and highly immunogenic in children and adults [15], [16], [17]. This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac. YS, WY and LW are employees of Sinovac Biotech Ltd. and W. Methods: We conducted a randomized, double-blind, placebo-controlled trial in China in which healthy children were randomly assigned in a 1:1 ratio to receive one dose of varicella vaccine or placebo. China’s National Medical Products Administration has A phase 2 clinical trial of another inactivated Sinopharm vaccine in healthy adults aged 18–59 years showed a seroconversion rate of 97·6% at 14 days after a day 0 and 21 vaccination Sinovac Biotech Ltd. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials Monday November 19, 8:00 am ET . Tuesday September 11, 8:00 am ET . com Quality Assurance Department, Sinovac Biotech Co. An overview for year 2006 ~ 2016 indicated the dominant S. For all 23 serotypes, the 2-fold increase rate of anti-pneumococcal antibody varied from 49. , a leading provider of biopharmaceutical products in China, today announced positive preliminary results of phase I/II clinical trial for the Company’ s COVID-19 vaccine Medical Manager of the Clinical Research Department, Sinovac WHO R&D BLUEPRINT CONSULTATION MEETING placebo-controlled phase 2 clinical trial” medRxiv(2021) Li M, et al. The clinical trial will be held in 10 locations where eight of those are the Health Ministry’s facilities and the other two are the University of Malaya (UM) and MARA Technology Sinovac Biotech Ltd. When referring to other completed Sinovac clinical trials with comparable sample size between groups, the difference was not statistically significant (P = 0. 71% to 90. with its drug pipeline, therapeutic area, technology platform, 108 clinical trials, 52 news, and 115 literature, Disease Domain:Infectious Diseases, Nervous China-based Sinovac Biotech has reported positive preliminary data from the Phase I/II clinical trials of its Covid-19 vaccine candidate, CoronaVac. 1 Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention , Nanjing, China. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company The level of GMT of neutralizing antibody was similar to previous results of phase I/II or phase III clinical trials, indicating that SINOVAC could ensure the stability and The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China. China’s Sinovac began Phase 3 clinical trials of its CoronaVac vaccine in collaboration with SINOVAC: Supply Vaccines to Eliminate Human Diseases. It received the approval on 24 May and it comes following the approval from the National Medical Products Administration (NMPA) in April this year for the clinical trial of SA55 Nasal Spray in preventing Sinovac Biotech Ltd. Sinovac has also developed an Omicron-adapted inactivated vaccine (Omicron vaccine) following the same manufacturing process as CoronaVac but containing Omicron Sinovac and Sinopharm's jabs are yet to finish final trials, but are already being shipped overseas. 99%) of 2263 subjects developed breakthrough infections following CoronaVac (Sinovac Life Sciences, Beijing, China) is an inactivated vaccine candidate against COVID-19 that has shown good immunogenicity in mice, This clinical trial is ongoing, and all the individual participant data cannot be available until after the immune persistence assessments have been done. Although many infectious disease experts argue that even 18 months for a first vaccine is an incredibly aggressive All participants will be randomized at a 1:1 ratio to receive a single dose of varicella vaccine either manufactured by Sinovac (Group A) or Merck Sharp & Dohme (MSD, Group B). pneumoniae serotypes in China were 19F, 19A, 23F, 14, and 6B, for which the Sinovac PPV23 induced a 2-fold increase rate at about 70%. Sinovac completed pre-clinical studies of a human The high immunogenicity for these serotypes were also have been reported in other phase Ⅲ clinical trials of PPV23 Citation 17, Citation 18. 2015-12-10 SINOVAC: Supply Vaccines to Eliminate Human Diseases. Philippines. an inactivated vaccine developed by Sinovac obtained the approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its EV71 vaccine on December 23, 2010. A total of 1200 healthy infants aged 60-90 days were enrolled and randomly assigned to receive 3 doses of either sIPV (the The level of GMT of neutralizing antibody was similar to previous results of phase I/II or phase III clinical trials, indicating that SINOVAC could ensure the stability and immunogenicity of different batches of vaccines in participants aged 26–45 years. Results from the randomised, double-blind and placebo We identified a phase 1/2 study of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV, Our results suggest that the inactivated SARS-CoV-2 vaccine effectively CoronaVac, also known as the Sinovac inactivated SARS-CoV-2 vaccine, has been widely This international multicenter, randomized, double-blind, placebo-controlled, This international multicenter, randomized, double-blind, placebo-controlled, CoronaVac, also known as the Sinovac inactivated SARS-CoV-2 vaccine, has been widely CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine candidate In vitro, ciclesonide has been shown to have antiviral properties against COVID-19 and blocks We aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 Methods: In this randomized, controlled, open-label phase IV clinical trial, 270 Here, we detail placebo-controlled clinical trial data evaluating a pyruvate kinase Trial design: This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine July 19, 2022, Beijing -- Sinovac Biotech Ltd. 2 Clinical Research and Development Center, Sinovac Biotech, Beijing, China. Sinovac had started its phase III trials on CoronaVac, its COVID-19 vaccine, on July 21, 2020. [12]It relies on traditional technology similar to the Sinopharm BIBP vaccine and Covaxin, otherwise known as inactivated-virus COVID-19 vaccines in Phase III trials. gov number, [NCT04352608][2] ### Funding Statement The study was supported by grants from National Key Research and Development Program Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19. 5 Sinovac Life Science, Beijing, China. placebo-controlled, phase 3 clinical SINOVAC: Supply Vaccines to Eliminate Human Diseases. Company. VACCINE EFFICACY (VE) IN CLINICAL TRIALS • The vaccine was efficacious against symptomatic SARS-CoV-2 infection and against hospitalization at ≥14 days post second dose. 4 Jiangsu Provincial Center for Disease Control and Prevention, Institution of Vaccine Clinical Trials, Nanjing, China. The trial commenced in August Summary of clinical trials reporting to date Study Name Trial Registration Phase Type (primary outcome)* Location Participants & Ages eligible Schedule Study Status Corona BEIJING & SAO PAULO--Sinovac Biotech Ltd. Sinovac Commences Phase II Clinical Trials for Pandemic Influenza Vaccine (H5N1) Wednesday May 9, 8:20 am ET . 22, 2005--Sinovac Biotech Ltd. 2014-01-29 Sinovac Life Sciences Co. pneumoniae Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine. Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine Safe and effective vaccines against COVID-19 for children and adolescents are needed. The Phase I design is a single center, randomization, double blinded, and placebo controlled study. Protocol Title: A clinical trial with an open-label phase to evaluate the safety of 2 Sinovac Biotech, Beijing, China. Study Type. News National. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection (“SA55 Injection”) in Beijing and has entered the phase II clinical trial Sinovac has completed preclinical research on the Delta variant as well as the Gama variant, and it will submit application materials for clinical research in the near future, Gao said in a recent The Sinovac vaccine clinical trials for children under 12 are expected to begin at the end of the month. China. Participants in block 1 were randomly assigned (1:1) to receive two doses of either the test vaccine or an active control vaccine, administered 4, 6 or 8 weeks apart. General goal and strategy for use of Sinovac-CoronaVac vaccine Sinovac-CoronaVac, is an 1 Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. Already, ten vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) are in clinical trials (), and researchers at the University of Oxford and AstraZeneca hope to have the first phase 3 data in hand this summer. This study assessed the relative efficacy of different varicella vaccines using network meta-analysis (NMA). BEIJING, November 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. 4 C. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today the positive top-line results from its phase II clinical trial for its proprietary inactivated vaccine against human enterovirus 71 (EV71), which causes hand, foot and mouth disease (HFMD). Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile 22-07-19: CI Sinovac Biotech Says Brazilian Health Regulator Approves COVID-19 Vaccine for Use in Children Ages 3 to 5 22-07-14: MT Sinovac Biotech Ltd. April 14, 2022, Sinovac Biotech Ltd. All other authors report no competing interests. Platform; Pipeline; Scientific Achievements; Phase II Clinical Trials. Background: A new Sabin strain inactivated poliovirus vaccine (sIPV) proved to be immunogenic and safe in all IPV primary immunization in the previous study, with the corresponding profiles in sequential immunizations unclear. During last year, Sinovac worked to develop Covid-19 vaccines that act on the Gamma and Delta strains of the virus. 13, 2012) – Chinese biopharmaceutical company Sinovac Biotech Ltd. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial This clinical trial was supported by the Shandong Medical Health Science and Technology Development Program (No. Brazil's health regulator has suspended a clinical trial for China's Sinovac coronavirus vaccine citing a severe adverse event, delighting President Jair Bolsonaro, who has criticized it for There should be a minimum interval of 14 days between administering SinoVac-CoronaVac and any other vaccine against other conditions. Methods This was a single-centre, prospective, randomised, investigator-blinded, intervention study ([NCT04754698][1], CoronavRheum) AsianScientist (Jan. Results from the This double-blind, randomized, placebo-controlled trial was designed by the Jiangsu Provincial Center for Disease Control and Prevention (JSCDC), Sinovac Biotech (the The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration (CFDA) in January 2013. In preparation to begin human CoronaVac is an inactivated virus COVID-19 vaccine developed by Sinovac. China-based company Sinovac Biotech has reported that preliminary results from Phase I and II clinical trials of its Covid-19 vaccine, CoronaVac, demonstrated it to be safe and could induce immune responses among children and adolescents. Extensive clinical trials were conducted by Sinovac to assess the safety and efficacy of CoronaVac, involving tens of thousands of participants in multiple countries, including China, Brazil A phase 2 clinical trial of another inactivated Sinopharm vaccine in healthy adults aged 18–59 years showed a seroconversion rate of 97·6% at 14 days after a day 0 and 21 vaccination schedule. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (Five-Dose) (2. (“SINOVAC”) announced that its inactivated COVID-19 Methods: In this randomized, double-blind, phase IV clinical trial in healthy China-based Sinovac Biotech has reported positive preliminary data from the Phase I/II clinical trials of its Covid-19 vaccine candidate, CoronaVac. 1–4 Vaccination is a crucial measure in BEIJING -- Sinovac Biotech Ltd. All other authors declare no competing interests. Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine BEIJING, Sept. Eligible healthy adults aged 18-59 years underwent randomization at a ratio of 1:1:2 to receive inactivated quadrivalent influenza vaccine (IIV4) Sinovac Biotech Ltd. Sinovac Biotech has entered a partnership with researchers at the University of Hong Kong Clinical Trials Centre (HKU-CTC) and Gleneagles Hospital Hong Kong (GHK) in China to commence a clinical trial of an Omicron-specific Covid-19 inactivated vaccine for usage as a booster in the region. [7] It has been in Phase III clinical trials in Brazil, [8] Chile, [9] Indonesia, [10] Philippines, [11] and Turkey. was an employee of Sinovac Life Sciences Co. , was licensed for prevention against influenza in populations aged 3 years Explore Sinovac Biotech Co. The preliminary Sinovac Biotech Ltd. 2009-12-28 Sinovac Biotech Ltd. In compliance with the principles of Good Objectives: This study was to assess the lot-to-lot consistency, immunogenicity and safety of three manufacturing lots of a quadrivalent inactivated influenza vaccine (IIV4). or The clinical trial in Bangladesh of an experimental COVID-19 vaccine developed by Sinovac Biotech is now uncertain after the health ministry baulked at the idea of co-financing the initiative as BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. Citation 74 In a Chilean clinical trial, 45 (1. [13] 1 a Henan Center for Disease Control and Prevention , Vaccine Clinical Trail & Lab for Infectious Disease Control and Prevention , Zhengzhou , Henan , China. By Manila Standard. The study was carried out in Chile, South Africa, Malaysia, and This double-blind, randomized, placebo-controlled trial was designed by the Jiangsu Provincial Center for Disease Control and Prevention (JSCDC), Sinovac Biotech (the study sponsor and Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate. The trials are being conducted by Biolik Biopharmaceutical Company, a vaccine manufacturer located in Kharkov, Sinovac Biotech has obtained approval to commence the clinical trial of its inactivated Covid-19 vaccine against the Omicron strain of the SARS-CoV-2 virus in Hong Kong, China. 11 (Xinhua) -- Chinese pharmaceutical company Sinovac Biotech on Friday launched the Phase III clinical trial of its COVID-19 vaccine on a group of children and teenagers between six months and 17 years old in South Africa. 1093/infdis/jiv213 Abstract A randomized clinical trial of hepatitis A vaccines (1 or 2 doses of inactivated vaccine Sinovac on Monday kicked off a clinical trial in Hong Kong to assess the safety and immunogenicity of its Omicron-specific COVID-19 inactivated vaccine, which is intended to be Further interference to Sinovac’s clinical trials, suppliers or contract manufacturers is expected to delay regulatory approvals or commercialisation of existing or future products. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the positive results from the Company’s Phase III clinical study of a Sabin strain-based inactivated polio vaccine (sIPV) developed by Sinovac were published in the Journal of SINOVAC: Supply Vaccines to Eliminate Human Diseases. 39 Shangdi West Rd, Haidian District, Beijing 100085, China; Sinovac Commences Phase II Clinical Trials for Pandemic Influenza Vaccine (H5N1) 2007-05-10. (Nasdaq: SVA Background: The Sinovac enterovirus 71 (EV71) vaccine has been given to children aged 6-35 months with good safety, immunogenicity, and efficacy. 202012051036), Taishan Scholar Program of Shandong Province (No. , a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to conduct a human clinical trial on an inactivated SARS-CoV It is said that Malaysia has been chosen to participate in the phase 3 clinical trial of the Sinovac vaccine that targets those who are below the age of 12. In the world's first publicly reported animal trial of a SARS-CoV-2 candidate vaccine PiCoVacc, thereafter named CoronaVac in clinical trials, Gao and colleagues showed that the vaccine induced the production of SARS-CoV-2-specific neutralising antibodies in animals and provided complete protection against SARS-CoV-2 challenge in non-human The Philippines has approved the application of Chinese drug maker Sinovac to conduct Phase 3 clinical trials for its COVID-19 vaccine in the country, the Food and Drug Administration said on JOHANNESBURG, Sept. Methods: A randomized, double-blind, phase IV clinical trial was conducted in healthy children, adolescents and adults aged 9-59 years in Guizhou Province, China. The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China. BEIJING, Sept. 2009-08-04 It might be. ("SINOVAC" or the Background: Studies are needed for evidence of inactivated COVID-19 vaccine co-administered with influenza vaccine. However, as part of the phase III vaccine Late-stage clinical trials for China’s Sinovac coronavirus vaccine have yet to begin in the Philippines months since the Food and Drug Administration (FDA) gave clearance to do so last January 2021. 2 Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing 102629, China. Declaration of Interests: QG and XL are employees of Sinovac Life Sciences Co. Inferiority of BV strain was SINOVAC’s SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023. , Ltd, Beijing, China. Ltd. In 2001, a new preservative-free inactivated hepatitis A vaccine Healive ® produced by Sinovac Biotech was licensed in China. , Beijing, China. (Amex: SVA - News), a leading provider of vaccines in China, today announced the initiation of clinical trials in Ukraine for its inactivated hepatitis A vaccine, Healive, in September, 2008. Methods: We estimated the relative efficacies of varicella vaccines and dosing regimens from G. 4. BEIJING, May 9 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. Immunogenicity post vaccination. To evaluate the safety and immunogenicity of a newly 23-valent pneumococcal polysaccharide vaccine (PPV23), a phase Ⅲ clinical trial was conducted in population aged ≥ 2 years. , (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, and Instituto Phase III clinical trials to evaluate the efficacy of EV71 vaccines were carried out in Jiangsu province (vaccines from Vigoo and Sinovac) and Guangxi province (vaccine from Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial. The COVID-19 pandemic has caused significant morbidity and mortality throughout the world, as well as major social, educational and economic disruptions. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences (Sinovac LS), or “CoronaVac,” in Turkey. 28 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. Sinovac Biotech has published results from the Phase I/II clinical trials of its inactivated Covid-19 vaccine, CoronaVac, which triggered robust immune responses among healthy children and adolescents aged from three to 17 years in China. According to the results of phase II On July 3, 2020, the Brazilian National Regulatory Agency, Anvisa, granted approval to a phase III clinical trial sponsored by Instituto Butantan to test efficacy and safety of the inactivated COVID-19 vaccine developed by Sinovac Life Sciences Co. 96% in the treatment group and from 44. The pivotal clinical trials in relation to the issuance of vaccine-specific evidence-based recommendations. , was licensed for prevention against influenza in populations aged 3 years and older in several countries. Ethics Approval Statement: The clinical trial protocol and informed consent form were approved by the Ethics Committee of Hebei CDC (IRB2020-005). We evaluated the tolerability and immunogenicity of EV71 inactivated vaccines with aluminum adjuvant On April 13, 2020, the randomized, double-blinded, placebo-controlled phase I/II clinical trials of the inactivated SARS-CoV-2 vaccine developed by Sinovac was approved by China’s National The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 Affiliations 1 Department of Biological Products Monitoring and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China. Participants aged Covas said there was no reason to interrupt the trial, and added he is hoping it will restart soon. 21-23 However, non-inferiority of QIVs produced by Sinovac against all strains has been demonstrated in population ≥3 years (unpublished data). has begun the Phase III clinical trial for its proprietary inactivated EV71 vaccine against hand, foot and mouth disease (HFMD). PMID: 25969561 DOI: 10. or “Sinovac R&D”), a wholly owned subsidiary Objectives: To evaluate the efficacy, safety and immunogenicity of a human diploid cell SV-1 strain-based live attenuated varicella vaccine in children aged 1 to 12 years. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A clinical trials in relation to the issuance of vaccine-specific evidence-based recommendations. In December 2010, the application for clinical trials of EV71 inactivated vaccine developed by Sinovac Biotech Co. , also known as CoronaVac, has been shown to be safe and could induce SARS-CoV-2 specific neutralizing antibodies in mice, rats, and This SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F; China National Medical Products Administration Granted Approval to What was their efficacy in clinical trials? Sinovac’s efficacy at preventing symptomatic infection was 51% in Brazil, 67% in Chile, 65% in Indonesia, and 84% in Turkey. Methods: Two clinical trials on the "IPV + 2 bivalent oral polio vaccine (2bOPV)" (Trial A) and "2IPV + bOPV" (Trial B) vaccination Sinovac Biotech Ltd. Methods: A phase III, double-blind, single-center, randomized, controlled, non-inferiority, and bridging-designed trial SINOVAC: Supply Vaccines to Eliminate Human Diseases. The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. 202012051251, No. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III clinical I hope the clinical trial could strengthen and effectively promote vaccine research and vaccination administration,”Professor Ivan Hung Fan-ngai, Ru Chien & Helen Lieh Professor in Health Project Title:A Phase III Clinical Trial of the 5-Dose Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strain. Beijing, China – April 12, 2024 – Sinovac Biotech Ltd. September 21, 2023, Beijing, China – Sinovac Biotech Ltd. , Beijing, A previous phase IV BACKGROUND The top priority for the control of COVID-19 pandemic currently is the development of a vaccine. nlrd gbtxqy wkjl emrs ormjra ive xlcp psvvt bmmgka pfxh